Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Otonomy stock | $1.89

Learn how to easily invest in Otonomy stock.

Otonomy Inc is a biotechnology business based in the US. Otonomy shares (OTIC) are listed on the NASDAQ and all prices are listed in US Dollars. Otonomy employs 56 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Otonomy

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OTIC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Otonomy stock price (NASDAQ: OTIC)

Use our graph to track the performance of OTIC stocks over time.

Otonomy shares at a glance

Information last updated 2021-10-23.
Latest market close$1.89
52-week range$1.14 - $6.98
50-day moving average $1.74
200-day moving average $1.97
Wall St. target price$6.30
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.84

Buy Otonomy shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Otonomy stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Otonomy price performance over time

Historical closes compared with the close of $1.89 from 2021-10-22

1 week (2021-10-15) -1.56%
1 month (2021-09-24) 7.39%
3 months (2021-07-23) 4.42%
6 months (2021-04-23) -17.47%
1 year (2020-10-23) -50.13%
2 years (2019-10-24) -14.86%
3 years (2018-10-24) 2.25
5 years (2016-10-24) 16.55

Otonomy financials

Revenue TTM $228,000
Gross profit TTM $-915,000
Return on assets TTM -31.69%
Return on equity TTM -94.45%
Profit margin 0%
Book value $1.37
Market capitalisation $107.1 million

TTM: trailing 12 months

Shorting Otonomy shares

There are currently 451,623 Otonomy shares held short by investors – that's known as Otonomy's "short interest". This figure is 13.7% down from 523,233 last month.

There are a few different ways that this level of interest in shorting Otonomy shares can be evaluated.

Otonomy's "short interest ratio" (SIR)

Otonomy's "short interest ratio" (SIR) is the quantity of Otonomy shares currently shorted divided by the average quantity of Otonomy shares traded daily (recently around 236451.83246073). Otonomy's SIR currently stands at 1.91. In other words for every 100,000 Otonomy shares traded daily on the market, roughly 1910 shares are currently held short.

However Otonomy's short interest can also be evaluated against the total number of Otonomy shares, or, against the total number of tradable Otonomy shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Otonomy's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Otonomy shares in existence, roughly 10 shares are currently held short) or 0.0087% of the tradable shares (for every 100,000 tradable Otonomy shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Otonomy.

Find out more about how you can short Otonomy stock.

Otonomy share dividends

We're not expecting Otonomy to pay a dividend over the next 12 months.

Otonomy share price volatility

Over the last 12 months, Otonomy's shares have ranged in value from as little as $1.14 up to $6.983. A popular way to gauge a stock's volatility is its "beta".

OTIC.US volatility(beta: 1.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Otonomy's is 1.818. This would suggest that Otonomy's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Otonomy overview

Otonomy, Inc. , a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc.

Frequently asked questions

What percentage of Otonomy is owned by insiders or institutions?
Currently 2.516% of Otonomy shares are held by insiders and 67.027% by institutions.
How many people work for Otonomy?
Latest data suggests 56 work at Otonomy.
When does the fiscal year end for Otonomy?
Otonomy's fiscal year ends in December.
Where is Otonomy based?
Otonomy's address is: 4796 Executive Drive, San Diego, CA, United States, 92121
What is Otonomy's ISIN number?
Otonomy's international securities identification number is: US68906L1052
What is Otonomy's CUSIP number?
Otonomy's Committee on Uniform Securities Identification Procedures number is: 68906L105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site